CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED FORM OF SUBSCRIPTION AGREEMENTSubscription Agreement • December 23rd, 2024 • Alps Global Holding Pubco • Services-health services
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED FORM OF SUBSCRIPTION AGREEMENTSubscription Agreement • October 2nd, 2024 • Alps Global Holding Pubco • Services-health services
FORM OF SUBSCRIPTION AGREEMENTSubscription Agreement • September 3rd, 2024 • Globalink Investment Inc. • Blank checks
FORM OF SUBSCRIPTION AGREEMENTSubscription Agreement • June 11th, 2024 • Globalink Investment Inc. • Blank checks
FORM OF SUBSCRIPTION AGREEMENTSubscription Agreement • May 24th, 2024 • Globalink Investment Inc. • Blank checks
In connection with the proposed business combination (the “Transaction”) by and among Globalink Investment Inc. a Delaware corporation (“Parent”), Alps Global Holding Pubco, a Cayman Islands exempted company (“Pubco”), Alps Biosciences Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of Pubco (“Merger Sub”), Alps Life Sciences Inc, a Cayman Islands exempted company (“Target”), , pursuant to that certain Amended and Restated Merger Agreement, dated as of May ___, 2024 (as it may be amended, modified or supplemented from time to time, the “Transaction Agreement”), by and among Parent, Pubco, Merger Sub, Target and certain other parties named therein, Pubco is seeking commitments from interested investors to purchase its ordinary shares, par value $0.0001 per share (the “Pubco Ordinary Shares”), for a purchase price of $10.00 per share (the “Per Share Purchase Price” and the aggregate purchase price for all Securities being referred to herein as the “Purchase Pr